When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...

Novo Nordisk is gradually ending production of human insulin pens, the drugmaker told Reuters, as it spends billions to ramp ...

The rise in type 2 diabetes cases globally presents opportunities for growth in the market for GLP-1 drugs like Ozempic and ...

The decision by Novo Nordisk to discontinue the insulin pens will force patients to revert to syringes, complicating diabetes care for millions of people.

Weight loss drugs are incredibly sought-after, but they’re also often difficult to obtain due to limited insurance coverage ...

Ahead of World Diabetes Day, Doctors Without Borders (MSF) called on pharmaceutical corporations Eli Lilly, Novo Nordisk, ...

Regulatory watchdog South African Health Products Regulatory Authority said these types of products pose a health risk to the public.

Only diabetes approval in SA Sahpra points out though that in South Africa, Ozempic is currently only registered for the ...

A recent study found semaglutide – the drug known as Ozempic – can improve knee pain in people with obesity and ...

SAHPRA cautions the public to not purchase and/or consume such products as their safety, efficacy, and quality have not been ...

These pose a health risk to the public. Sahpra cautions the public to not purchase and/or consume such products as their ...

SAHPRA has not approved, or verified any of those for them to be able to be available in the market.” SAHPRA adds that ...